<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01740089</url>
  </required_header>
  <id_info>
    <org_study_id>PEG-IFNа-2</org_study_id>
    <nct_id>NCT01740089</nct_id>
  </id_info>
  <brief_title>Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C</brief_title>
  <official_title>Multicenter Open-label Randomized Prospective Clinical Study of Efficacy and Safety of Algeron (Cepeginterferon Alfa-2b) in Comparison With PegIntron (Peginterferon Alfa-2b) in the Combined Treatment of Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate the noninferiority of Algeron 1.5 and 2.0
      μg/kg/week in combination with ribavirin compared to PegIntron in combination with ribavirin
      in the treatment of chronic hepatitis C, and to determine therapeutic dose of Algeron.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After 12 weeks of treatment, an assessment of treatment efficacy was performed, i.e. rates of
      rapid (after 4 weeks) and early (after 12 weeks) virologic responses according to serum HCV
      RNA level PCR data. In patients without virologic response after 12 weeks, AVT was
      discontinued, and they were withdrawn from the study. Patients with EVR were enrolled in a
      follow-up period. During the follow-up period, patients of the first and the second group
      will receive Algeron in the selected therapeutic dose in combination with ribavirin, patients
      of the third group - PegIntron in combination with ribavirin during 12 or 36 weeks (depending
      on a genotype of the virus), afterwards they will be followed up without therapy for 24
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Randomized Patients Achieving Early Virologic Response (EVR) - Negative PCR Result for HCV RNA (&lt; 15 IU/ml) or ≥ 2log10 Decrease of Viral Load After 12 Weeks of Study Treatment.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Randomized Patients Achieving Rapid Virologic Response (RVR) - Negative PCR Result for HCV RNA (&lt; 15 IU/ml) After 4 Weeks of Treatment.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Randomized Patients Achieving Sustained Virologic Response (SVR) - Negative PCR Result for HCV RNA (&lt; 15 IU/ml) 24 Weeks After Last Dose of Study Treatment.</measure>
    <time_frame>24 weeks after last dose of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Have Undetectable HCV RNA (&lt; 15 IU/ml) at the End of Treatment.</measure>
    <time_frame>After 24 weeks of treatment for patients with genotype 2 or 3 and after 48 weeks of treatment for patients with genotype 1 or 4.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Weeks 0, 12, 24, 48 (for patients with genotype 1 or 4) and 24 weeks after last dose of study treatment</time_frame>
    <description>Number of randomized patients with neutralizing antibodies to IFN alfa on weeks 0, 12, 24, 48 (for patients with genotype 1 or 4) and 24 weeks after last dose of study treatment.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Hepatitis</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Algeron 1.5 μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight &lt; 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight &gt; 105 kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Algeron 2.0 μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight &lt; 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight &gt; 105 kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PegIntron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight &lt; 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight &gt; 105 kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Algeron</intervention_name>
    <description>1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously</description>
    <arm_group_label>Algeron 1.5 μg/kg</arm_group_label>
    <arm_group_label>Algeron 2.0 μg/kg</arm_group_label>
    <other_name>cepeginterferon alfa-2b</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PegIntron</intervention_name>
    <description>1.5 μg/kg/week subcutaneously in combination with ribavirin</description>
    <arm_group_label>PegIntron</arm_group_label>
    <other_name>Peginterferon alfa-2b</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>800-1400 mg/day orally</description>
    <arm_group_label>Algeron 1.5 μg/kg</arm_group_label>
    <arm_group_label>Algeron 2.0 μg/kg</arm_group_label>
    <arm_group_label>PegIntron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent to participate in the study.

          2. Hepatitis С virus infection (genotypes 1а, 1b, 2, 3, 4) confirmed by a positive
             quantitative PCR (HCV RNA &gt; 50 IU/ml).

          3. Males and females aged from 18 to 70 years inclusive.

          4. Body mass index of 18 - 30 kg/m inclusive.

          5. Increased ALT level (&gt; 40, &lt; 400 IU/L), documented at least twice within the last 6
             months.

          6. Preserved protein synthetic liver function (i.e. INR &lt; 1.7, albumin &gt; 35 g/l).

          7. No signs of hepatic encephalopathy or abdominal fluid retention according to clinical
             and ultrasound examination.

          8. Fertile patients and their partners agree to use barrier contraception throughout the
             study and 7 months after its completion.

        Exclusion Criteria:

          1. Intolerance of IFN alpha formulations, ribavirin or any components of these drugs
             according to the past medical history.

          2. Infection by hepatitis B virus or HIV.

          3. Past history of HCV treatment with IFN alfa or pegylated IFN alfa formulations.

          4. Administration of interferons and/or interferon inducing drugs for any indication
             within 1 month prior to the enrollment into the study.

          5. Cholestatic hepatitis (conjugated bilirubin, alkaline phosphatase, ALT levels of more
             than 5 ULN).

          6. Decompensated liver cirrhosis confirmed by laboratory findings (Child-Pugh class B, С)
             or ultrasound examination.

          7. Any documented autoimmune diseases.

          8. Hematologic (hemoglobin &lt; 130 g/L for males and &lt; 120 g/L for females; neutrophils &lt;
             1.5 х109/L; platelets &lt; 90 х109/L) or biochemical abnormalities (creatinine level of
             more than 1.5 ULN, creatinine clearance less than 50 mL/min).

          9. Documented diagnosis of hemoglobinopathies (e.g., thalassemia major, sickle-cell
             anemia).

         10. Heavy depression, any other mental disorders, which in the Investigator's opinion can
             be contraindications for antiviral treatment.

         11. Epilepsy and/or other functional disorders of the central nervous system.

         12. Abnormal thyroid function (TTH level beyond the normal values).

         13. Malignant neoplasms.

         14. Pregnancy, lactation period.

         15. Severe comorbidities (for example, severe hypertension, severe coronary heart disease,
             decompensated diabetes mellitus), which in the Investigator's opinion can be
             contraindications for antiviral treatment.

         16. Documented rare hereditary diseases, such as intolerance of lactose, sucrose,
             fructose, lactase deficiency or glucose-galactose malabsorption.

         17. Current alcohol or drug abuse, which in the Investigator's opinion can be
             contraindications for antiviral treatment or restrict treatment compliance.

         18. Simultaneous participation in other clinical trials or prior participation in this or
             another clinical trial within less than 30 days after its completion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olga Znoyko, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moscow State University of Medicine and Dentistry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marina Maevskaya, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Moscow State Sechenov Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Svetlana Kizhlo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health Department &quot;Center for Prevention and Control of AIDS and Infectious Diseases&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Natalia Petrochenkova</last_name>
    <role>Principal Investigator</role>
    <affiliation>Smolensk State Medical Academy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Semen Maximov</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moscow State University of Medicine and Dentistry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Firaja Nagimova</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kazan State Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vladimur Yakovlev</last_name>
    <role>Principal Investigator</role>
    <affiliation>7. St. Petersburg State Institution of Health &quot;Clinical Infectious Diseases Hospital named SP Botkin&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moscow State University of Medicine and Dentistry</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2012</study_first_posted>
  <results_first_submitted>March 1, 2015</results_first_submitted>
  <results_first_submitted_qc>July 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2015</results_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Cepeginterferon alfa</keyword>
  <keyword>Peginterferon</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Algeron 1.5 μg/kg</title>
          <description>Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight &lt; 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight &gt; 105 kg).
Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously</description>
        </group>
        <group group_id="P2">
          <title>Algeron 2.0 μg/kg</title>
          <description>Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight &lt; 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight &gt; 105 kg).
Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously</description>
        </group>
        <group group_id="P3">
          <title>PegIntron</title>
          <description>PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight &lt; 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight &gt; 105 kg).
PegIntron: 1.5 μg/kg/week subcutaneously in combination with ribavirin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First 12 Weeks of Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="48">Withdrawn due to:
AE before W12 (n=1) Withdrew consent before W12 (n=1)</participants>
                <participants group_id="P3" count="48">Withdrawn due to:
AE before W12 (n=2)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After 12 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43">Withdrawn due to:
No EVR (n=3) AE (n=2) No EOT (n=1) Non-compliance (n=1)</participants>
                <participants group_id="P2" count="45">Withdrawn due to:
Withdrawn consent (n=1) No EVR (n=1) Non-compliance (n=1)</participants>
                <participants group_id="P3" count="37">Withdrawn due to:
No EVR (n=4) AE (n=5) Non-attendance of visit (n=1) Withdrawn consent (n=1)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>During randomization, patients were stratified by gender, age, viral load, and HCV genotype. The mITT-analysis included all randomized patients received at least one dose of investigational products, who were not withdrawn from the study at its beginning due to serious violations of the inclusion/non-inclusion criteria.</population>
      <group_list>
        <group group_id="B1">
          <title>Algeron 1.5 μg/kg</title>
          <description>Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight &lt; 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight &gt; 105 kg).
Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously</description>
        </group>
        <group group_id="B2">
          <title>Algeron 2.0 μg/kg</title>
          <description>Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight &lt; 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight &gt; 105 kg).
Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously</description>
        </group>
        <group group_id="B3">
          <title>PegIntron</title>
          <description>PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight &lt; 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight &gt; 105 kg).
PegIntron: 1.5 μg/kg/week subcutaneously in combination with ribavirin</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" lower_limit="30" upper_limit="39"/>
                    <measurement group_id="B2" value="34" lower_limit="29" upper_limit="42"/>
                    <measurement group_id="B3" value="36" lower_limit="30" upper_limit="41"/>
                    <measurement group_id="B4" value="35" lower_limit="30" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV genotype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>HCV 1b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCV 1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCV 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCV 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Initial Viral load</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>High (&gt;8х10^5 IU/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low (≤8х10^5 IU/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Interleukin 28B (IL-28B) genotype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>C/C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C/T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T/T</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Randomized Patients Achieving Early Virologic Response (EVR) - Negative PCR Result for HCV RNA (&lt; 15 IU/ml) or ≥ 2log10 Decrease of Viral Load After 12 Weeks of Study Treatment.</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Algeron 1.5 μg/kg</title>
            <description>Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight &lt; 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight &gt; 105 kg).
Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Algeron 2.0 μg/kg</title>
            <description>Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight &lt; 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight &gt; 105 kg).
Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>PegIntron</title>
            <description>PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight &lt; 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight &gt; 105 kg).
PegIntron: 1.5 μg/kg/week subcutaneously in combination with ribavirin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Randomized Patients Achieving Early Virologic Response (EVR) - Negative PCR Result for HCV RNA (&lt; 15 IU/ml) or ≥ 2log10 Decrease of Viral Load After 12 Weeks of Study Treatment.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Randomized Patients Achieving Rapid Virologic Response (RVR) – Negative PCR Result for HCV RNA (&lt; 15 IU/ml) After 4 Weeks of Treatment.</title>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Algeron 1.5 μg/kg</title>
            <description>Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight &lt; 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight &gt; 105 kg).
Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Algeron 2.0 μg/kg</title>
            <description>Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight &lt; 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight &gt; 105 kg).
Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously</description>
          </group>
          <group group_id="O3">
            <title>PegIntron</title>
            <description>PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight &lt; 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight &gt; 105 kg).
PegIntron: 1.5 μg/kg/week subcutaneously in combination with ribavirin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Randomized Patients Achieving Rapid Virologic Response (RVR) – Negative PCR Result for HCV RNA (&lt; 15 IU/ml) After 4 Weeks of Treatment.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Randomized Patients Achieving Sustained Virologic Response (SVR) – Negative PCR Result for HCV RNA (&lt; 15 IU/ml) 24 Weeks After Last Dose of Study Treatment.</title>
        <time_frame>24 weeks after last dose of study treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Algeron (n=100)</title>
            <description>the comparative inter-group analysis of efficacy was performed for patients of groups 1 and 2 received Algeron (n=100), because after 12 weeks of therapy and analysis of data, all patients of the first and second groups continued receive Algeron in a chosen therapeutic dose 1.5 µg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PegIntron (n=50)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Randomized Patients Achieving Sustained Virologic Response (SVR) – Negative PCR Result for HCV RNA (&lt; 15 IU/ml) 24 Weeks After Last Dose of Study Treatment.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Have Undetectable HCV RNA (&lt; 15 IU/ml) at the End of Treatment.</title>
        <time_frame>After 24 weeks of treatment for patients with genotype 2 or 3 and after 48 weeks of treatment for patients with genotype 1 or 4.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Algeron (n=100)</title>
            <description>the comparative inter-group analysis of efficacy was performed for patients of groups 1 and 2 received Algeron (n=100), because after 12 weeks of therapy and analysis of data, all patients of the first and second groups continued receive Algeron in a chosen therapeutic dose 1.5 µg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PegIntron (n=50)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Have Undetectable HCV RNA (&lt; 15 IU/ml) at the End of Treatment.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Immunogenicity</title>
        <description>Number of randomized patients with neutralizing antibodies to IFN alfa on weeks 0, 12, 24, 48 (for patients with genotype 1 or 4) and 24 weeks after last dose of study treatment.</description>
        <time_frame>Weeks 0, 12, 24, 48 (for patients with genotype 1 or 4) and 24 weeks after last dose of study treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Algeron (n=100)</title>
            <description>the comparative inter-group analysis of efficacy was performed for patients of groups 1 and 2 received Algeron (n=100), because after 12 weeks of therapy and analysis of data, all patients of the first and second groups continued receive Algeron in a chosen therapeutic dose 1.5 µg/kg.</description>
          </group>
          <group group_id="O2">
            <title>PegIntron (n=50)</title>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity</title>
          <description>Number of randomized patients with neutralizing antibodies to IFN alfa on weeks 0, 12, 24, 48 (for patients with genotype 1 or 4) and 24 weeks after last dose of study treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria [severe depression at Visit 1], who was not considered to be enrolled in the study due to serious protocol violation.</desc>
      <group_list>
        <group group_id="E1">
          <title>Algeron (n=101)</title>
          <description>The safety analysis included 101 patients received at least 1 dose of Algeron (taking into account one patient withdrawn at early stages of the study due to a protocol violation [severe depression by the Beck's scale before the first injection], who was withdrawn from the mITT-analysis)</description>
        </group>
        <group group_id="E2">
          <title>PegIntron (n=50)</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>drug-induced pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>phlegmonous appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 leucopenia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="101"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Grade 2 leucopenia</sub_title>
                <counts group_id="E1" events="45" subjects_affected="45" subjects_at_risk="101"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Grade 3 leucopenia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="101"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Grade 1 neutropenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Grade 2 neutropenia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="101"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Grade 3 neutropenia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="101"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Grade 4 neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Grade 1 lymphopenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Grade 1 thrombocytopenia</sub_title>
                <counts group_id="E1" events="47" subjects_affected="47" subjects_at_risk="101"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Grade 2 thrombocytopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Grade 1 anemia</sub_title>
                <counts group_id="E1" events="73" subjects_affected="73" subjects_at_risk="101"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Grade 2 anemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="101"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Increased TTH level</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="101"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="101"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="101"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="101"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" events="86" subjects_affected="86" subjects_at_risk="101"/>
                <counts group_id="E2" events="49" subjects_affected="49" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Asthenia (weakness, fatigue)</sub_title>
                <counts group_id="E1" events="63" subjects_affected="63" subjects_at_risk="101"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Grade I decreased body weight</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="101"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Grade II decreased body weight</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="101"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="101"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="52" subjects_affected="52" subjects_at_risk="101"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="101"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="101"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Irritability, emotional lability</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="101"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Sleep disorders</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="101"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry cough</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="101"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dyspnoe (including dyspnoe after exercises)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rhinitis, nasal congestion</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="101"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hoarseness, throat irritation, sore throat</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="101"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Skin itch</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="101"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="101"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Skin dryness and exfoliation</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="101"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Stomatitis and gingivitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Blepharitis and conjunctivitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yulia Linkova Medical Director</name_or_title>
      <organization>Biocad</organization>
      <phone>+7 (495) 992 66 28 ext 930</phone>
      <email>linkova@biocad.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

